The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...
Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...
Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results